Deipolyi, Amy R. http://orcid.org/0000-0003-3144-386X
England, Ryan W.
Ridouani, Fourat
Riedl, Christopher C.
Kunin, Henry S.
Boas, F. Edward
Yarmohammadi, Hooman
Sofocleous, Constantinos T.
Funding for this research was provided by:
NIH/NCI Cancer Center Support Grant (P30 CA008748)
Breast Cancer Research Foundation
Article History
Received: 20 August 2019
Accepted: 6 November 2019
First Online: 15 November 2019
Compliance with Ethical Standards
:
: Dr. Deipolyi reports personal fees from BTG, Inc., personal fees from Dova Pharmaceuticals, outside the submitted work. Dr. Boas is a co-founder of Claripacs, LLC, and received a research grant and supplies from Guerbet, research support from GE, research supplies from Bayer, and a research grant and speaker fees from Society of Interventional Oncology, sponsored by Guerbet; he is also an investor in Labdoor, Qventus, CloudMedx, Notable Labs, and Xgenomes. Dr. Yarmohammadi received research grants from the Thompson Foundation and Guerbet. Dr. Sofocleous received consulting fees from Terumo and consulting fees and research funding from BTG and Johnson and Johnson. The other authors have no disclosures.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of retrospective study, formal consent is not required.
: This study has obtained institutional IRB approval, and the need for informed consent was waived due to its retrospective nature.
: For this type of study, consent for publication is not required.